Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezetimibe + Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia
NCT03867318Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Apr 2000
- Primary completion
- Nov 2001
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ezetimibe in hypercholesterolemia and heterozygous familial hypercholesterolemia (HeFH) (2 arms), sponsored by Organon & Co. Primary endpoints: Percentage of Participants Achieving Target Low-Density-Lipoprotein Cholesterol (LDL-C) Levels of <=100 mg/dL at Week 14, Percentage of Participants With an Adverse Event at 14 weeks and 1 more. Started Apr 2000; status: completed.
02
Drugs
ezetimibe
03
Conditions
hypercholesterolemiaheterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT03867318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03867318.